Cellular Basis of Steroid Glaucoma
Principal Investigator
Jorge Alvarado, MD
University of California, San Francisco
San Francisco, CA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 1995 - March 31, 1997
Grant ID
G1995402
Summary
Glaucoma is a blinding disease affecting millions of Americans. This disease causes blindness because the eye pressure becomes elevated and this pressure can destroy the optic nerve without which one cannot see. Treatment of the eye with steroid eye drops can result in an increase in pressure inside the eye, and in some individuals steroids can actually cause glaucoma, and loss of vision. The purpose of the research outlined in this grant proposal is to discover the reasons that steroid treatment can cause increased pressure, and to use this knowledge to develop potential means to prevent and treat this type of glaucoma. It is even likely that such new treatment approaches may help us develop new medications for other types of glaucoma. There are two layers of cells through which the clear fluid in the eye, or aqueous humor, must pass as it drains from the eye to return to the circulation. Normally, the aqueous can flow through small spaces which lie between the cells in these layers. Through study of human cells kept alive and growing in a healthy state, we are seeking to understand how the passage of fluid through them can be regulated. Early results from these experiments indicate that with steroid treatment, the channels between cells are narrowed, and the flow is clearly reduced.
Related Grants
National Glaucoma Research
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
Role of a Key Gene, Angptl7, in Steroid-Induced Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dan Stamer, PhD
Current Organization
Duke University School of Medicine
National Glaucoma Research
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
Enhancing Access to Glaucoma Care Using Artificial Intelligence
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Benjamin Xu, MD, PhD
Current Organization
University of Southern California
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute